Search

Your search keyword '"Hirsch, Heather A."' showing total 175 results

Search Constraints

Start Over You searched for: Author "Hirsch, Heather A." Remove constraint Author: "Hirsch, Heather A."
175 results on '"Hirsch, Heather A."'

Search Results

1. Communities at the Forefront: Elevating Girls' Sports through Local Programs. Encompassing Data from the Sports 4 Life National and Regional Initiatives. A Women's Sports Foundation Research Report

2. Making SEL Assessment Work: Ten Practitioner Beliefs

3. An Evaluation of Achieving Condom Empowerment (ACE)-Plus in Foster Care Agencies in New York City

5. The Use of ACOG Guidelines: Perceived Contraindications to IUD and Implant Use Among Family Planning Providers

7. Data from Maveropepimut-S, a DPX-Based Immune-Educating Therapy, Shows Promising and Durable Clinical Benefit in Patients with Recurrent Ovarian Cancer, a Phase II Trial

8. Table S1 from Maveropepimut-S, a DPX-Based Immune-Educating Therapy, Shows Promising and Durable Clinical Benefit in Patients with Recurrent Ovarian Cancer, a Phase II Trial

12. Maveropepimut-S, a DPX-Based Immune-Educating Therapy, Shows Promising and Durable Clinical Benefit in Patients with Recurrent Ovarian Cancer, a Phase II Trial

13. Abstract 2274: An immune-educating therapy, Maveropepimut-S, elicits a diverse and active anti-tumor T cell response in patients with advanced recurrent ovarian cancer

14. Supplementary Figures 1 - 3 from Preclinical Evaluation of the WEE1 Inhibitor MK-1775 as Single-Agent Anticancer Therapy

15. Supplementary Figure Legends, Table Legends, Figure 1, Tables 1 - 4 from Evaluating TBK1 as a Therapeutic Target in Cancers with Activated IRF3

16. Data from Evaluating TBK1 as a Therapeutic Target in Cancers with Activated IRF3

17. Supplementary Figure Legend from Preclinical Evaluation of the WEE1 Inhibitor MK-1775 as Single-Agent Anticancer Therapy

18. Supplementary Table 1 from Preclinical Evaluation of the WEE1 Inhibitor MK-1775 as Single-Agent Anticancer Therapy

19. Supplementary Data from Reverse Translating Molecular Determinants of Anti–Programmed Death 1 Immunotherapy Response in Mouse Syngeneic Tumor Models

22. Abstract OT2-20-01: Neoadjuvant survivin immunotherapy maveropepimut-S (MVP-S) to increase Th1 immune response in Ki67-high hormone receptor positive (HR+) early-stage breast cancer

23. 646 Neoadjuvant immunotherapy combining maveropepimut-S (MVP-S) with letrozole decreases Ki67 and increases Th1 immune response in hormone receptor positive (HR+) early-stage breast cancer (ESBC)

24. 913 Translational analysis of advanced metastatic bladder cancer patients treated with IO combination maveropepimut-S, cyclophosphamide, and pembrolizumab

28. Abstract CT035: Safety, preliminary efficacy and pharmacodynamic (PD) analysis of maveropepimut-S, intermittent low-dose cyclophosphamide and pembrolizumab in patients with advanced, metastatic bladder cancer

29. Neoadjuvant survivin-targeted immunotherapy maveropepimut-S (MVP-S) to increase Th1 immune response in Ki67-high hormone receptor-positive (HR+) early-stage breast cancer (ESBC).

31. Proteomic analysis of plasma exosomes as biomarkers of response to MVP-S based immunotherapy

32. Reverse Translating Molecular Determinants of Anti–Programmed Death 1 Immunotherapy Response in Mouse Syngeneic Tumor Models

38. An Epigenetic Switch Involving NF-[kappa]B, Lin28, Let-7 MicroRNA, and IL6 Links Inflammation to Cell Transformation

40. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project

45. Abstract 4053: Genetic and molecular profiling of ICOS hi CD4 T cells demonstrates clonal expansion of Th1 effector cells following JTX-2011 treatment in subjects with solid tumors

46. Differential analysis for high density tiling microarray data

47. Rank-statistics based enrichment-site prediction algorithm developed for chromatin immunoprecipitation on chip experiments

48. Abstract 1678: Integrated genomics and histology based studies of triple negative breast cancer identify ICOS as potential target for therapeutic intervention

50. ICONIC: Biologic and clinical activity of first in class ICOS agonist antibody JTX-2011 +/- nivolumab (nivo) in patients (pts) with advanced cancers.

Catalog

Books, media, physical & digital resources